Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Merus N.V. CS (MRUS)

Merus N.V. CS (MRUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END

ONCY : 1.0300 (+1.98%)
ONC.TO : 1.38 (unch)
PYXS : 4.15 (-1.21%)
AZN : 68.05 (-0.31%)
LLY : 778.18 (unch)
MRUS : 44.75 (-0.36%)
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

/PRNewswire/ -- USA News Group - Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy...

ONC.TO : 1.38 (unch)
ONCY : 1.0300 (+1.98%)
PYXS : 4.15 (-1.21%)
AZN : 68.05 (-0.31%)
LLY : 778.18 (unch)
MRUS : 44.75 (-0.36%)
Breakthroughs in Pancreatic Cancer Treatment: How FDA Designations are Changing the Game

USA News Group – Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the...

ONCY : 1.0300 (+1.98%)
ONC.TO : 1.38 (unch)
PYXS : 4.15 (-1.21%)
AZN : 68.05 (-0.31%)
LLY : 778.18 (unch)
MRUS : 44.75 (-0.36%)
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

/PRNewswire/ -- USA News Group - The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in...

ONC.TO : 1.38 (unch)
ONCY : 1.0300 (+1.98%)
MRUS : 44.75 (-0.36%)
GH : 17.96 (+1.53%)
MDT : 86.92 (unch)
NVDA : 898.55 (-0.44%)
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 26, 2023 – USA News Group  –  The seriousness of pancreatic cancer continues to grow, with increasing alarm since...

ONCY : 1.0300 (+1.98%)
ONC.TO : 1.38 (unch)
MRUS : 44.75 (-0.36%)
GH : 17.96 (+1.53%)
MDT : 86.92 (unch)
NVDA : 898.55 (-0.44%)
Pancreatic Cancer's Alarming Surge in Young Adults Sparks Research into New Treatments

USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in April 2023, showing a rising incidence of pancreatic cancer...

ONCY : 1.0300 (+1.98%)
ONC.TO : 1.38 (unch)
MRUS : 44.75 (-0.36%)
GH : 17.96 (+1.53%)
MDT : 86.92 (unch)
NVDA : 898.55 (-0.44%)
Wall Street Analysts Believe Merus N.V. (MRUS) Could Rally 114.58%: Here's is How to Trade

The consensus price target hints at an 114.6% upside potential for Merus N.V. (MRUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

MRUS : 44.75 (-0.36%)
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of 19.63% and 27.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

MRUS : 44.75 (-0.36%)
CDTX : 0.8500 (+0.94%)
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates

Aligos Therapeutics, Inc. (ALGS) delivered earnings and revenue surprises of -8.16% and 36.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

ALGS : 0.9660 (-1.33%)
MRUS : 44.75 (-0.36%)
Analysts Estimate Merus N.V. (MRUS) to Report a Decline in Earnings: What to Look Out for

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MRUS : 44.75 (-0.36%)
TSVT : 5.25 (-2.42%)

Barchart Exclusives

2 Growth Stocks With 20% to 40% Upside in 2024
Both of these companies’ innovative products present excellent long-term opportunities for investors seeking growth in the stock market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar